Strong Momentum Drives Stock to Record Levels
On 2 December 2025, Fredun Pharmaceuticals recorded an intraday high of Rs.1999, setting a fresh all-time peak for the stock. This milestone reflects a sustained upward momentum, with the stock registering gains for five consecutive trading sessions. Over this period, the stock has delivered a cumulative return of 9.4%, outperforming its sector by 0.95% on the day of the new high.
The stock’s performance is further underscored by its position relative to key moving averages. Fredun Pharmaceuticals is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a robust technical trend that supports the recent price strength.
Market Context and Comparative Performance
While the broader market, represented by the Sensex, opened lower by 316.39 points and was trading at 85,308.86 at the time, Fredun Pharmaceuticals demonstrated resilience. The Sensex remains close to its own 52-week high of 86,159.02, trading just 1% below that level and maintaining a bullish stance as it trades above its 50-day moving average, which itself is positioned above the 200-day moving average.
Fredun Pharmaceuticals’ one-year performance stands out distinctly, with a return of 148.18% compared to the Sensex’s 6.31% over the same period. This substantial outperformance highlights the company’s strong position within the Pharmaceuticals & Biotechnology sector.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
See What's Driving the Rally →
Financial Performance Underpinning the Rally
Fredun Pharmaceuticals’ recent financial disclosures provide insight into the factors supporting its stock price trajectory. The company’s net sales for the latest quarter stood at Rs.145.30 crores, reflecting a growth rate of 35.35%. Operating profit margins remain strong, with an operating profit to interest ratio reaching 2.89 times, indicating healthy coverage of interest expenses.
Net profit after tax (PAT) for the quarter was Rs.9.73 crores, showing a growth rate of 127.9%. This marks the sixth consecutive quarter of positive results, underscoring consistent operational performance. Over the past year, the company’s profits have risen by 63.5%, complementing the stock’s price appreciation.
Return on capital employed (ROCE) is reported at 20.2%, reflecting efficient utilisation of capital resources. The enterprise value to capital employed ratio stands at 3.4, suggesting an attractive valuation relative to the company’s capital base. Compared to its peers, Fredun Pharmaceuticals is trading at a discount to average historical valuations, which may be a factor in its recent market performance.
Long-Term Growth and Market Position
Over the last year, Fredun Pharmaceuticals has delivered a total return of 148.18%, significantly outpacing the broader market indices. The company’s net sales have grown at an annualised rate of 39.73%, while operating profit has expanded at 55.03% annually. This sustained growth trajectory has contributed to the stock’s upward momentum and the achievement of its new 52-week high.
The stock’s 52-week low was Rs.635, illustrating the scale of appreciation over the past year. Such a rise reflects both the company’s operational progress and favourable market dynamics within the Pharmaceuticals & Biotechnology sector.
Want to dive deeper on Fredun Pharmaceuticals ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Market Participation and Ownership Structure
Despite the company’s size and strong performance, domestic mutual funds currently hold no stake in Fredun Pharmaceuticals. This absence of mutual fund ownership may reflect a cautious stance or differing assessment of the company’s valuation or business prospects. Nonetheless, the stock’s recent price action indicates robust demand from other market participants.
The Pharmaceuticals & Biotechnology sector continues to be a focus area for investors, with Fredun Pharmaceuticals emerging as a notable performer within this space. The stock’s ability to maintain gains above multiple moving averages and its consistent quarterly results contribute to its current market standing.
Summary of Key Metrics
Fredun Pharmaceuticals’ stock price has reached Rs.1999, its highest level in 52 weeks and all time. The stock has gained 9.4% over the last five trading days and outperformed its sector by nearly 1% on the day of the new high. The company’s net sales for the latest quarter were Rs.145.30 crores, with net profit after tax at Rs.9.73 crores. Operating profit to interest coverage is at 2.89 times, and ROCE stands at 20.2%. Over the past year, the stock has delivered a return of 148.18%, compared to the Sensex’s 6.31%.
Fredun Pharmaceuticals’ recent price performance and financial results illustrate a period of strong momentum and operational progress, culminating in the attainment of a new 52-week high. This milestone reflects the company’s position within the Pharmaceuticals & Biotechnology sector and its ability to sustain growth amid broader market fluctuations.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
